41. BioSpace : CCIS : Search Results For Indication = 'Graft Vs. Host Disease' approved products, please log in above or subscribe. 13 Search Results for Indication = graft vs. host disease . View as worksheet. http://www.biospace.com/ccis/search.cfm?RXTargetID=57004

42. Graft-vs.-host Disease graftvs.-host disease is an immune attack on the recipient by cells from a donor. donor and recipient are well matched, graft-vs.-host disease can still occur http://www.chclibrary.org/micromed/00049690.html

Main Search Index Definition Description Causes ... Resources Graft-vs.-host disease Definition Graft-vs.-host disease is an immune attack on the recipient by cells from a donor. Description The main problem with transplanting organs and tissues is that the recipient host does not recognize the new tissue as its own. Instead, it attacks it as foreign in the same way it attacks germs, to destroy it. If immunogenic cells from the donor are transplanted along with the organ or tissue, they will attack the host, causing graft vs. host disease. The only transplanted tissues that house enough immune cells to cause graft vs. host disease are the blood and the bone marrow. Blood transfusions are used every day in hospitals for many reasons. Bone marrow transplants are used to replace blood forming cells and immune cells. This is necessary for patients whose cancer treatment has destroyed their own bone marrow. Because bone marrow cells are among the most sensitive to radiation and chemotherapy , it often must be destroyed along with the cancer. This is true primarily of leukemias, but some other cancers have also been treated this way. Even if the donor and recipient are well matched, graft-vs.-host disease can still occur. There are many different elements involved in generating immune reactions, and each person is different, unless they are identical twins. Testing can often find donors who match all the major elements, but there are many minor ones that will always be different. How good a match is found also depends upon the urgency of the need and some good luck.

43. Gale Encyclopedia Of Medicine Graft-vs.-host Disease graftvs.-host disease. The only transplanted tissues that house enough immune cells to cause graft vs. host disease are the blood and the bone marrow. http://www.findarticles.com/cf_0/g2601/0006/2601000605/p1/article.jhtml

@import url(/css/us/style.css); @import url(/css/us/searchResult1.css); @import url(/css/us/articles.css); Advanced Search Home Help IN all publications this publication Automotive Business Computing Entertainment Health News Reference Sports YOU ARE HERE Articles Content provided in partnership with Print friendly Tell a friend Find subscription deals Graft-vs.-host disease by J. Ricker Polsdorfer Definition Graft-vs.-host disease is an immune attack on the recipient by cells from a donor. Description The main problem with transplanting organs and tissues is that the recipient host does not recognize the new tissue as its own. Instead, it attacks it as foreign in the same way it attacks germs, to destroy it. If immunogenic cells from the donor are transplanted along with the organ or tissue, they will attack the host, causing graft vs. host disease. The only transplanted tissues that house enough immune cells to cause graft vs. host disease are the blood and the bone marrow. Blood transfusions are used every day in hospitals for many reasons. Bone marrow transplants are used to replace blood forming cells and immune cells. This is necessary for patients whose cancer treatment has destroyed their own bone marrow. Because bone marrow cells are among the most sensitive to radiation and chemotherapy, it often must be destroyed along with the cancer. This is true primarily of leukemias, but some other cancers have also been treated this way. Even if the donor and recipient are well matched, graft-vs.-host disease can still occur. There are many different elements involved in generating immune reactions, and each person is different, unless they are identical twins. Testing can often find donors who match all the major elements, but there are many minor ones that will always be different. How good a match is found also depends upon the urgency of the need and some good luck.

44. Photopheresis For Chronic Graft Vs. Host Disease Photopheresis for Chronic graft vs. host disease. This educational resource is supported by an unrestricted educational grant from therakos.logo.gif http://www.bloodline.net/stories/storyReader$3374

Bloodline Home About Call for Papers Free Membership ... Search Educational Features Image Atlas Case Studies Private Lectures Conference Reviews ... Glossary Resources Conference Calendar Hematology Links Full Text Journals Classifieds Specialties BMT/Stem Cell Cord Blood Thrombosis Hemostasis ... Veterinary News Hematology News Blood News Update Discussion Today's Discussion Create New Topic List by Topic Members Join Now Login Photopheresis for Chronic Graft vs. Host Disease This educational resource is supported by an unrestricted educational grant from Published as part of Blood and Marrow Transplantation Reviews - Volume 12, Issue 4 Sunil Abhyankar, MD If you don't see a checkmark, download QuickTime Download: PC Mac 10.5 MB Help Viewing Private Lectures requires QuickTime Check here to determine if QuickTime is properly installed on your computer. Email questions and comments to PLS.Support@cjp.com Return to the BMTR - Vol. 12, Issue 4, contents page. Carden Jennings Publishing Co., Ltd. Featured Resources Optimizing Outcomes with IGIV Therapy Bloodline Reviews Volume 3, Issue 2

45. Extracorporeal Phtopheresis In Acute Graft Vs. Host Disease Extracorporeal Phtopheresis in Acute graft vs. host disease. This educational resource is supported by an unrestricted educational grant from therakos.logo.gif http://www.bloodline.net/stories/storyReader$3375

Bloodline Home About Call for Papers Free Membership ... Search Educational Features Image Atlas Case Studies Private Lectures Conference Reviews ... Glossary Resources Conference Calendar Hematology Links Full Text Journals Classifieds Specialties BMT/Stem Cell Cord Blood Thrombosis Hemostasis ... Veterinary News Hematology News Blood News Update Discussion Today's Discussion Create New Topic List by Topic Members Join Now Login Extracorporeal Phtopheresis in Acute Graft vs. Host Disease This educational resource is supported by an unrestricted educational grant from Published as part of Blood and Marrow Transplantation Reviews - Volume 12, Issue 4 Hildegard T. Greinix, MD If you don't see a checkmark, download QuickTime Download: PC Mac 10.5 MB Help Viewing Private Lectures requires QuickTime Check here to determine if QuickTime is properly installed on your computer. Email questions and comments to PLS.Support@cjp.com Return to the BMTR - Vol. 12, Issue 4, contents page. Carden Jennings Publishing Co., Ltd. Featured Resources Optimizing Outcomes with IGIV Therapy Bloodline Reviews Volume 3, Issue 2

46. Acute And Chronic Syngeneic Graft-vs-Host Disease Acute and Chronic Syngeneic graftvs-host disease. Complexity of Effector Mechanisms in Cyclosporine-Induced Syngeneic graft-vs-host disease. http://bbmt.cjp.com/stories/storyReader$51

Menu Home Purpose and Scope Masthead Author Instructions ... Search CJP Online Journals BloodLine Heart Surgery Forum Journal Center Acute and Chronic Syngeneic Graft-vs-Host Disease Complexity of Effector Mechanisms in Cyclosporine-Induced Syngeneic Graft-vs-Host Disease Allan D. Hess, Christopher J. Thoburn, Weiran Chen and Louis R. Horwitz Administration of the immunosuppressive drug, cyclosporine after syngeneic or autologous bone marrow transplantation elicits a T-lymphocyte-dependent autoimmune syndrome similar to graft-vs-host disease (GVHD). The onset of this autoaggression syndrome, termed syngeneic GVHD, is associated with the development of a highly restricted repertoire of CD8 autoreactive T cells that recognize a peptide from the invariant chain, termed CLIP, presented by MHC class II molecules. Clonal analysis reveals two distinct subsets of autoreactive T cells defined by their activation requirement for either the N terminal or the C terminal flanking regions of CLIP and by their cytokine profile. The present studies reveal that the autoreactive T cell clones requiring the N terminal flanking region of CLIP produce type 1 cytokines (interferon [IFN]- y , interleukin [IL]-2, and tumor necrosis factor- a ). In contrast, the autoreactive T cell clones that require the C terminal flanking region of CLIP produce type 2 cytokines (IL-4, IL-10, Transforming growth factor-

47. Lymphohematopoietic Graft-vs.-Host Reactions Without GVHD Lymphohematopoietic graftvs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based http://bbmt.cjp.com/stories/storyReader$96

Menu Home Purpose and Scope Masthead Author Instructions ... Search CJP Online Journals BloodLine Heart Surgery Forum Journal Center Lymphohematopoietic Graft-vs.-Host Reactions without GVHD Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen Michele R. Pelot, Denise A. Pearson, Kirsten Swenson, Guiling Zhao, Jessica Sachs, Yong-Guang Yang, Megan Sykes 5.3.Pelot Carden Jennings Publishing Co., Ltd. Current Edition Biology of Blood and Marrow Transplantation Laboratory Hematology Blood and Marrow Transplantation Reviews Heart Surgery Forum

48. Learn About Cord Blood, Stem Cells, And Us cells? Q What are possible uses of cord blood stem cells in the future? Q What is graft vs. host disease (GVHD)? A graft vs. host http://www.cordbloodfamilytrust.com/faq/index.cfm?faqID=84

49. ASCO - Browse By Meeting - Alemtuzumab Prevents Acute Graft-vs.-host Disease (aG globulin and corticosteroids to methotrexate and cyclosporine (or tacrolimus) does not change the rates of acute graftvs-host disease, early infections http://www.asco.org/ac/1,1003,_12-002636-00_18-0023-00_19-00101296,00.asp?Abstra

50. Genomics|HuGENet EJournal On Graft Vs Host Abstract none. Health outcome(s) Identification of the major health outcome(s) studied, Acute graft versus host disease (GVHD), grade III or IV; http://www.cdc.gov/genomics/hugenet/ejournal/GraftVsHostAbst.htm

Your browser does not support script home ejournal Relation of an Interleukin-10 Promoter Polymorphism to Graft-versus-Host Disease and Survival after Hematopoietic-Cell Transplantation back to report May 6, 2004 Abstraction Template Article Reference Complete the bibliographic reference for the article according to AJE format. Lin M, et al. Relation of an interleukin-10 promoter polymorphism to graft-versus-host disease and survival after hematopoietic-cell transplantation. NEJM. 2003;349:2201-2210. Category of HuGE information Specify the types of information (from the list below) available in the article: Prevalence of gene variant Gene-disease association Gene-environment interaction Gene-gene interaction Genetic test evaluation/monitoring Gene-disease associations Study hypotheses or purpose The authors study hypotheses or main purpose for conducting the study Hypothesis: Polymorphisms in cytokine promoter regions that enhance or suppress cytokine expression may affect the severity of the inflammatory response involved in GVHD and associated survival. This study is meant to replicate the findings of other studies showing associations between a variety of cytokine promoter-region single-nucleotide polymorphisms and GVHD outcomes Gene(s) Identification of the following: Gene name Chromosome location Gene product/function Alleles OMIM # Gene name Chromosome location Gene product/function : Interleukin 10; anti-inflammatory cytokine, influences Th2 differentiation

51. Blackwell Synergy - Cookie Absent This article reviews acute graft vs. host disease (GVHD) as a complication of orthotopic liver transplantation (OLT). The incidence http://www.blackwell-synergy.com/links/doi/10.1111/j.1600-6143.2004.00406.x/enha

 Home An Error Occurred Setting Your User Cookie A cookie is a small amount of information that a web site copies onto your hard drive. Synergy uses cookies to improve performance by remembering that you are logged in when you go from page to page. If the cookie cannot be set correctly, then Synergy cannot determine whether you are logged in and a new session will be created for each page you visit. This slows the system down. Therefore, you must accept the Synergy cookie to use the system. What Gets Stored in a Cookie? Synergy only stores a session ID in the cookie, no other information is captured. In general, only the information that you provide, or the choices you make while visiting a web site, can be stored in a cookie. For example, the site cannot determine your email name unless you choose to type it. Allowing a web site to create a cookie does not give that or any other site access to the rest of your computer, and only the site that created the cookie can read it. Please read our for more information about data collected on this site.

52. Dermatology Times : Photochemotherapy Relieves Case Of Graft Vs. Host Disease.(B Dermatology Times Photochemotherapy Relieves Case of graft vs. host disease.(Brief Article) @ HighBeam Research. Read Dermatology http://static.highbeam.com/d/dermatologytimes/april012000/photochemotherapyrelie

eLibrary Web Tour Become a Member ... Customer Support Question / Keyword(s): Advanced Search Current Article: Photochemotherapy Relieves Case of Graft vs. Host Disease.(Brief Article) Start D Dermatology Times April 01, 2000 ... Photochemotherapy Relieves Case of Graft vs. Host Disease.(Brief Article) Photochemotherapy Relieves Case of Graft vs. Host Disease.(Brief Article) Dermatology Times; April 01, 2000; Wilson, Fred Wilson, Fred Dermatology Times April 01, 2000 mycophenolate mofetil, bone marrow, skin thickness, marrow transplant, treatments, dr, sclerotic changes, puva bath, sclerodermic type, patient, patients, immunosuppressive therapy, peter, ulm, joint mobility Ulm, Germany A bone marrow transplant recipient with chronic sclerodermic graft-versus-host disease (GVHD) showed a strong response to UVA1 phototherapy combined with mycophenolate mofetil (CellCept) immunosuppressive therapy. The case of a 42-year-old man with a 1994 diagnosis of chronic myeloid leukemia was described in the Journal of the American Academy of Dermatology by researchers from the the University of Ulm. The patient

53. Graft-vs-Host Disease : On Medical Dictionary Online graftvs-host disease defined on the Free Online Medical Dictionary. Medical terminology definitions graft-vs-host disease. The clinical entity http://www.online-medical-dictionary.org/?q=Graft-vs-Host Disease

54. Clinical Trial: Sargramostim In Reducing Graft-Versus-Host Disease In Patients W Determine the efficacy of sargramostim (GMCSF) to mobilize CD34+ hematopoietic stem cells in donors and to reduce graft-vs-host disease in patients after http://www.clinicaltrials.gov/ct/gui/show/NCT00053157?order=50

55. Graft Versus Host Disease GVHD Clinical Significance of Skin Biopsies in the Diagnosis and Management of graftvs-host disease in Early Postallogeneic Bone Marrow Transplantation Youwen Zhou http://www.edae.gr/graft.html

HELLENIC ASSOCIATION DERMATOLOGY - VENEREOLOGY GRAFT VERSUS HOST DISEASE (GVHD) Acute Graft Versus Host Disease Adoptive immunotherapy for relapsed multiple myeloma after allogeneic bone marrow transplantation (BMT): evidence for a graft-versus-myeloma effect Advances in Small Bowel and Multivisceral Transplantation Jacques Pirenne, MD, PhD. XVIII International Congress of the Transplantation Society Approaches to Treating Graft-Versus-Host Disease Approaches to Treating Graft-Versus-Host Disease. Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation Public Health Service National Institutes of Health bone marrow transplants Bullous Esophagitis and GVHD diagnosishealth. BULLOUS ESOPHAGITIS DUE TO CHRONIC GVHD Causes, incidence, and risk factors graft-versus-host reaction Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy. Grundmann-Kollmann M, Behrens S, Gruss C, Gottlober P, Peter RU, Kerscher M. Department of Dermatology, University of Ulm, Germany. J Am Acad Dermatol 2000 Jan; 42(1 Pt 1): 134-6. Chronic sclerodermic graft-versus-host disease refractory to immunosuppressive treatment responds to UVA1 phototherapy Grundmann-Kollmann M, Behrens S, Gruss C: J Am Acad Dermatol 2000 Jan; 42(1 Pt 1): 134-6[Medline].

56. Graft Vs. Host Disease Study: News: UI Health Care Health Care researcher is serving as a coprincipal investigator for a National Institutes of Health (NIH) grant to study graft versus host disease (GVHD) in http://www.uihealthcare.com/news/news/2001/01/22graft.html

News by Medical Specialty 2004 News Archive 2003 News Archive 2002 News Archive ... 1999 News Archive - UI Health Care's digital library Read this month's health-e-newsletter Send comments and questions to staff@uihealthcare.com University of Iowa UI Health Care News: Week of January, 2001 UI researcher helps lead study of bone marrow transplantation complication A University of Iowa Health Care researcher is serving as a co-principal investigator for a National Institutes of Health (NIH) grant to study Graft versus Host Disease (GVHD) in children. GVHD is a common and life-threatening complication that can follow bone marrow transplantation. Frederick Goldman, M.D., UI associate professor of pediatrics and director of the UI Pediatric Bone Marrow Transplant Unit, received $460,000 of the $2.3 million, five-year NIH grant for his component of the study. The study's lead investigator is Andrew Gilman, M.D., of Children's Mercy Hospital in Kansas City, Mo. The overall study goals are to evaluate the effectiveness of hydroxychloroquine, a new immunosuppressive drug, for treating GVHD and to better under what causes the disease, Goldman said. More than 100 pediatric bone marrow transplant centers nationwide will participate in the trial, which is sponsored by the federal Children's Oncology Group. The study will ultimately involve more than 300 pediatric patients.

57. Graft-vs-Host Disease After Solid Organ Transplant graftvs-host disease (GVHD), a common complication of allogeneic bone marrow transplantation, also may be seen after solid organ transplantation and in http://www.medscape.com/viewarticle/452197

58. Imaging In Bone Marrow Transplantation graftvs-host disease. GVHD is a significant posttransplantation complication that occurs in about 50% of allogeneic transplants. http://www.medscape.com/viewarticle/417694_2

59. JW Dermatology -- Sign In Late Occurrence of graftvs-host disease. Valks R et al. Late appearance of acute graft-vs-host disease after suspending or tapering immunosuppressive drugs. http://dermatology.jwatch.org/cgi/content/full/2001/227/2

Physician-authored summaries and The New England Journal of Medicine Please sign in for full text All customers have full-text access to the Journal Watch publication(s) to which they have a subscription. Other registered users have access to Journal Watch Online content older than six months and may request e-mail notification of current contents. Subscribers and Registered Users User Name Password If you are a subscriber using Journal Watch Online for the first time you must activate and choose a password Remember my user name and password. Forgotten your password? If you do not use cookies sign in here (After you click the 'Sign In' button you may have to wait for several seconds. Thank you for your patience.) First-Time Users and Other Visitors To subscribe click here. If you would like free e-mail notification of current content and/or free access to all content older than 6 months register here If you would like full access to Journal Watch Online for 7 days for $19

60. Graft-Versus-Host Disease graftvs-host disease After Solid Organ Transplant Sclerodermatous graft-vs-host disease clinical and pathological study of 17 patients. http://www.thedoctorsdoctor.com/diseases/graft_vs_host_disease.htm

Background Graft-versus-host disease (GVH) is a disease of modern medicine. It most commonly occurs in bone marrow transplant patients receiving an allogeneic transplant of immunocompetent lymphocytes. The donor cytotoxic T lymphocytes attack the recipient's organs including skin, gut, liver, and mucous membranes. It may occur in 50% of recipients of allogeneic bone marrow transplants. GVH may also occur after maternofetal blood transfusions, intrauterine exchange transfusions, and administration of non-irradiated blood products to patients with metastatic malignancies or with immunodeficiencies. OUTLINE Epidemiology Disease Associations Pathogenesis Gross Appearance and Clinical Variants ... Internet Links EPIDEMIOLOGY CHARACTERIZATION SYNONYMS GVH DISEASE ASSOCIATIONS CHARACTERIZATION SOLID ORGAN TRANSPLANTATION Graft-vs-Host Disease After Solid Organ Transplant H. Evin Gulbahce, MD, Charlotte A. Brown, PhD, FACMG, Myra Wick, PhD, Miriam Segall, PhD, and Jose Jessurun, MD Am J Clin Pathol 2003;119:568-573 Abstract quote

A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z

Page 3     41-60 of 90    Back | 1  | 2  | 3  | 4  | 5  | Next 20